Zulassungserweiterung Yescarta beim r/r FL
Oncol Res Treat 2022;45:622 –623 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - September 29, 2022 Category: Cancer & Oncology Source Type: research
Das inoperable NSCLC im Stadium III im Dialog
Oncol Res Treat 2022;45:I –XII (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - September 29, 2022 Category: Cancer & Oncology Source Type: research
Prelims
Oncol Res Treat 2022;45(suppl 2):1 –3 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - September 27, 2022 Category: Cancer & Oncology Source Type: research
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022, Wien: Abstracts
naOncol Res Treat 2022;45:5 –346 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - September 27, 2022 Category: Cancer & Oncology Source Type: research
The Burden of Fear of Cancer Recurrence in Genitourinary Cancers: A Prospective Study (NCT04535921)
Conclusion: This study is the first to describe FCR in patients with genitourinary cancers. Surgical treatment improves FCR. Sociodemographic factors like age, female gender, employment, and education were observed to influence FCR levels. Strong correlations between FCR, QoL, and psychological distress indicate the importance of further clinical screening for FCR. Tumor-related factors however seem to play a less prominent role. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - September 26, 2022 Category: Cancer & Oncology Source Type: research
The burden of fear of cancer recurrence in genitourinary cancers – a prospective study (NCT04535921)
Introduction: Fear of cancer recurrence (FCR) is a challenging and often unaddressed concern and predictive factors for high FCR remain unclear. Therefore, the aim of the current study is to assess predictive factors for high FCR in patients undergoing surgery for genitourinary cancer.
Materials and methods: Overall, 525 patients were prospectively included. FCR was measured using the validated FCR7-questionnaire prior to surgery and after receipt of the histological result. Family-support, religiousness, quality-of-life-impairment due to FCR and distress were determined. Patient and tumor-related factors were compared wi...
Source: Oncology Research and Treatment - September 26, 2022 Category: Cancer & Oncology Source Type: research
Stereotactic radiotherapy for adrenal metastases: a multi-institutional review of patient characteristics and outcomes. Turkish Society for Radiation Oncology SBRT Group Study (TROD SBRT 10-004)
Conclusion: A satisfactory LC rate was achieved for adrenal metastasis via SBRT. A higher BED10 and fraction dose were positive prognostic factors for tumor control. However, the main problem is DM in these patients and systemic treatment options are needed to be improved. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - September 16, 2022 Category: Cancer & Oncology Source Type: research
Society Bulletins
Oncol Res Treat 2022;45:556 –560 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - August 31, 2022 Category: Cancer & Oncology Source Type: research
PharmaNews
Oncol Res Treat 2022;45:548 –555 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - August 31, 2022 Category: Cancer & Oncology Source Type: research
PharmaNews
Oncol Res Treat 2022;45:546 –547 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - August 31, 2022 Category: Cancer & Oncology Source Type: research
Behandlung unfitter AML-Patient*innen: Paradigmenwechsel
Oncol Res Treat 2022;45:544 –545 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - August 31, 2022 Category: Cancer & Oncology Source Type: research
OnkoImmun 17
Oncol Res Treat 2022;45:I –XII (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - August 31, 2022 Category: Cancer & Oncology Source Type: research
Current research status of metronomic chemotherapy in combination treatment of breast cancer
Background: Metronomic chemotherapy (MCT), termed sustained low-dose administration with minimal toxicity, is a new modality of conventional chemotherapy, a verified therapy alternative, and has acquired significant recognition and interest in oncology. Numerous clinical trials of MCT in combination with other treatments, including targeted therapies, biologics, and endocrine therapy, are in progress to obtain better results.
Summary: We systematically reviewed the most recent clinical data from Pubmed/Medline, ClinicalTrials.gov, and the European Clinical Trials Database. We comprehensively described the clinical benefit...
Source: Oncology Research and Treatment - August 19, 2022 Category: Cancer & Oncology Source Type: research
Administration of valproic acid improves the survival of patients with glioma treated with postoperative radiotherapy
Objective The aim of this study was to investigate the impact of valproic acid(VPA) on survival and prognosis of patients with glioma who underwent postoperative radiotherapy.
Methods We obtained the case data with brain glioma who underwent postoperative radiotherapy from 2012 January to 2019 December. This cohort was heterogeneous . We conducted single factor analysis and multiple factors analysis of the basic features, pathological classification, therapies of all 185 patients using Kaplan-Meier survival curve, log-rank survival significance test and Cox-regression analysis model.
Results By the end of the last follo...
Source: Oncology Research and Treatment - August 19, 2022 Category: Cancer & Oncology Source Type: research
Prelims
Oncol Res Treat 2022;45(suppl 1):1 –3 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - August 4, 2022 Category: Cancer & Oncology Source Type: research
